Study of EBP50 in Prostate Cancer
Author Information
Author(s): Bartholow Tanner L, Becich Michael J, Chandran Uma R, Parwani Anil V
Primary Institution: University of Pittsburgh School of Medicine
Hypothesis
Does EBP50 expression differ in various prostate tissue types, including cancerous and benign tissues?
Conclusion
EBP50 expression is significantly lower in metastatic prostate cancer compared to other tissue types.
Supporting Evidence
- EBP50 staining was significantly lower in metastatic prostate cancer compared to normal and benign tissues.
- HGPIN specimens showed the highest EBP50 staining intensity.
- Statistical analysis revealed significant differences in EBP50 expression across different prostate tissue types.
Takeaway
This study looked at a protein called EBP50 in prostate cancer and found that it is less present in advanced cancer compared to normal or benign tissues.
Methodology
Immunohistochemistry was used to analyze EBP50 expression in tissue microarrays from various prostate tissue types.
Limitations
The study did not have follow-up information on patient outcomes to correlate EBP50 expression with prognosis.
Participant Demographics
Average ages were 32 for normal donors, 63 for adjacent normal tissue, 67 for benign hyperplasia, 63 for high-grade neoplasia, 64 for primary cancer, and 70 for metastatic cancer.
Statistical Information
P-Value
p = 0.006
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website